Oncolin Therapeutics Announces Its New ‘Super Cell Blocker’, ONC-127, Has Shown Effectiveness In Treating Cancer

Oncolin Therapeutics, Inc., (OTCBB:OCOL) announces that its new Super Cell Blocker, ONC-127, has been effective in treating animals that have been implanted with human tumors in their brains. This technology has extended the life of animals in a preclinical environment. The Super Cell Blocker, ONC-127, drug candidate is a major breakthrough in inhibiting a process known as glycolysis which “starves the tumor” by blocking its ability to provide energy for the cell to live.

More: continued here

Filed under: Cancer on May 17th, 2008